Amgen reported preliminary success for dazodalibep, its Horizon Therapeutics-acquired fusion protein, in a Phase 3 trial for Sjögren’s disease. The company said the candidate met the primary objective in a mid-to-late stage evaluation, positioning the program as a potential first therapy in a common autoimmune indication with limited approved options. The readout suggests the program could compete with existing immunology approaches and sets up further regulatory discussions depending on final datasets and the second Phase 3 trial requirement. Amgen has placed the asset within a broader autoimmune portfolio where late-stage catalysts can materially change valuation. The Sjögren’s market is crowded with investigational efforts but remains underserved for durable symptom control, and a positive Phase 3 can quickly shift competitive expectations. For the sector, the Horizon-to-Amgen integration continues to pay off if the remaining Phase 3 effort confirms the efficacy profile and maintains a tolerable safety signal.